Incyte (INCY) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $24.1B
- As of Nov 5, 2026
- P/E
- 59.57x
- Trailing twelve months
- P/B
- 4.27x
- Latest reported equity
- P/S
- 4.00x
- Trailing twelve months
- ROE
- 7.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $24.1B
- As of Nov 5, 2026
- P/E
- 59.57x
- Trailing twelve months
- P/B
- 4.27x
- Latest reported equity
- P/S
- 4.00x
- Trailing twelve months
- ROE
- 7.2%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
59.57x
P/B
4.27x
P/S
4.00x
Earnings and dividend metrics▾
Earnings
EPS
$1.98
Earnings per share
BPS
$27.66
Book value per share
ROE
7.2%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $1.98 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $27.66 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 7.2%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 14.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.37B+14.0%
$1.14B
Jul–Sep '24
$1.37B
Jul–Sep '25
$1.56B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 29, 2026.
- Earnings per share decreased 282.9% from the same quarter a year earlier.
- Revenue increased 14.0% from the same quarter a year earlier.
- Operating income decreased 259.5% from the same quarter a year earlier.
- Net income decreased 285.1% from the same quarter a year earlier.
Filed Oct 29, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Tray ThomasPrincipal Accounting Officer · Nov 3, 2026Open-market sale610 shares · $73KAvg. price $118.9621,126 shares held after
- CAGNONI PABLO JPresident, Global Head of R&D · Oct 15, 2026Open-market sale2,642 shares · $298KAvg. price $112.71183,200 shares held after
- CAGNONI PABLO JPresident, Global Head of R&D · Oct 15, 2026Option exercise2,642 shares · $174KAvg. price $65.7615
Show 4 price lots
- 839 shares × $71.93$60K
- 925 shares × $64.25$59K
- 455 shares × $61.18$28K
- 423 shares × $61.76$26K
- Heeson LeeEVP, Head of Incyte Intl · Oct 1, 2026Shares withheld for taxes463 shares · $54KAvg. price $117.1437,578 shares held after
- HARRIGAN EDMUNDDirector · Sep 30, 2026Grant or award206 shares · $25KAvg. price $121.3523,225 shares held after
- Clancy Paul JDirector · Sep 30, 2026Grant or award203 shares · $25KAvg. price $121.3525,838 shares held after
- BAKER BROS. ADVISORS LPDirector · Sep 30, 2026Grant or award644 shares · $0Avg. price $0
Show 2 price lots
- 322 shares × $0$0
- 322 shares × $0$0
- Gardner David HEVP, Chief Strategy Officer · Sep 22, 2026Shares withheld for taxes920 shares · $117KAvg. price $126.9315,904 shares held after
- CAGNONI PABLO JPresident, Global Head of R&D · Sep 15, 2026Open-market sale23,218 shares · $2.8MAvg. price $120.494
Show 2 price lots
- 13,985 shares × $120.49$1.7M
- 9,233 shares × $120.5$1.1M
- CAGNONI PABLO JPresident, Global Head of R&D · Sep 15, 2026Option exercise23,218 shares · $1.5MAvg. price $66.3852
Show 4 price lots
- 9,233 shares × $71.93$664K
- 6,477 shares × $64.25$416K
- 4,551 shares × $61.18$278K
- 2,957 shares × $61.76$183K
- Basi Ramitpal KEVP, Human Resources · Aug 25, 2026Shares withheld for taxes504 shares · $65KAvg. price $129.7210,993 shares held after
- CAGNONI PABLO JPresident, Global Head of R&D · Aug 19, 2026Open-market sale10,801 shares · $1.4MAvg. price $125.56183,200 shares held after
- CAGNONI PABLO JPresident, Global Head of R&D · Aug 12, 2026Open-market sale10,803 shares · $1.3MAvg. price $120.04194,001 shares held after
- CAGNONI PABLO JPresident, Global Head of R&D · Aug 5, 2026Open-market sale10,640 shares · $1.3MAvg. price $122.69204,804 shares held after
- Mayes Patrick AEVP & Chief Scientific Officer · Aug 5, 2026Open-market sale2,207 shares · $274KAvg. price $123.9961,441 shares held after
- Mayes Patrick AEVP & Chief Scientific Officer · Aug 5, 2026Option exercise2,207 shares · $235KAvg. price $106.4763,648 shares held after
- Mayes Patrick AEVP & Chief Scientific Officer · Aug 3, 2026Open-market sale6,055 shares · $729KAvg. price $120.4361,441 shares held after
- Mayes Patrick AEVP & Chief Scientific Officer · Aug 3, 2026Option exercise6,055 shares · $638KAvg. price $105.4367,496 shares held after
- CAGNONI PABLO JPresident, Global Head of R&D · Jul 31, 2026Open-market sale15,888 shares · $1.9MAvg. price $119.7215,444 shares held after
- Mayes Patrick AEVP & Chief Scientific Officer · Jul 31, 2026Open-market sale41,899 shares · $5.0MAvg. price $119.458
Show 11 price lots
- 14,661 shares × $119.46$1.8M
- 6,171 shares × $119.43$737K
- 5,332 shares × $119.42$637K
- 4,695 shares × $119.39$561K
- 2,864 shares × $119.4$342K
- 2,293 shares × $119.41$274K
- 2,187 shares × $119.47$261K
- 1,643 shares × $119.51$196K
- 1,642 shares × $119.38$196K
- 326 shares × $121.69$40K
- 85 shares × $122.19$10K
- Mayes Patrick AEVP & Chief Scientific Officer · Jul 31, 2026Option exercise12,482 shares · $935KAvg. price $74.9171
Show 2 price lots
- 9,459 shares × $72.27$684K
- 3,023 shares × $83.2$252K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QThe company said it recorded a net loss of $784.8 million (net loss of $3.86 per basic and diluted share) for the 3 months ended September 30, 2026, compared with net income of $424.2 million in the same period a year earlier. Net income for the 9 months was $104.1 million, compared with $987.4 million in the same period last year.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KThe company said its total revenue for Q3 2026 was $1.56 billion and total net sales were $1.32 billion, each up 14% from Q3 2025. Jakafi/Jakafi XR net sales reached $827 million, up 4%, and Opzelura net sales reached $255 million, up 36%.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KIncyte said that 8 directors were elected at the Annual Meeting of Shareholders held on June 8, 2026. Julian C. Baker received 140,340,036 votes for, 33,157,541 votes against and 723,111 abstentions.Published Oct 1, 2026 · Filed Jun 9, 2026Read the summary →
- The company said it recorded a net loss of $784.8 million (net loss of $3.86 per basic and diluted share) for the 3 months ended September 30, 2026, compared with net income of $424.2 million in the same period a year earlier. Net income for the 9 months was $104.1 million, compared with $987.4 million in the same period last year.Read the full analysis →
- The company said its total revenue for Q3 2026 was $1.56 billion and total net sales were $1.32 billion, each up 14% from Q3 2025. Jakafi/Jakafi XR net sales reached $827 million, up 4%, and Opzelura net sales reached $255 million, up 36%.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Incyte (INCY) stock information
NASDAQ
Incyte (INCY) is listed on NASDAQ. Its market capitalization is about $24.1B. On trailing-twelve-month earnings the P/E ratio is 59.57, and the P/B ratio is 4.27. Return on equity is 7.2%. These figures are computed in-house from official filings and are reference information only.
Incyte — frequently asked questions
- What is the P/E ratio of Incyte (INCY)?
- On a trailing-twelve-month basis, INCY trades at a P/E ratio of 59.57. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Incyte?
- INCY has a market capitalization of about $24.1B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.